EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The SAPIEN M3 system for transcatheter mitral valve replacement: A new era begins

Michail Penteris, Konstantinos Lampropoulos

Cardiovascular Revascularization Medicine · 2025-10 · 79 · 120-125

DOI: 10.1016/j.carrev.2025.06.034 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Revascularization Medicine, 2025-10. Verfasst von Michail Penteris und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Electronic address: michpent@med.duth.gr. Hauptthemen laut MEDLINE: Mitral Valve, Heart Valve Prosthesis, Mitral Valve Insufficiency, Heart Valve Prosthesis Implantation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitral regurgitation (MR) remains a prevalent and undertreated valvular heart disease, particularly in patients at prohibitive surgical risk. While mitral transcatheter edge-to-edge repair (M-TEER) offers a less invasive alternative, anatomical limitations and incomplete MR reduction in some patients have fueled the development of transcatheter mitral valve replacement (TMVR) technologies. The SAPIEN M3 system (Edwards Lifesciences, Irvine, CA, USA) introduces a novel, fully percutaneous TMVR approach utilizing a two-component system: a self-expanding nitinol dock that encircles the subvalvular apparatus and a balloon-expandable SAPIEN 3 valve adapted for the mitral position. This design minimizes the risk of left ventricular outflow tract (LVOT) obstruction and enables stable, anatomy-independent anchoring without requiring annular calcification. Early feasibility studies have shown high technical success rates (>85 %), effective MR reduction, and a favorable safety profile in high-risk patients. The ongoing ENCIRCLE trial and a planned European post-market study aim to further evaluate the system's safety, durability, and long-term outcomes. Despite promising early results, challenges remain, including procedural complexity, the potential for LVOT obstruction, and limited long-term durability data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral ValveHeart Valve ProsthesisMitral Valve InsufficiencyHeart Valve Prosthesis ImplantationCardiac CatheterizationHumansProsthesis DesignTreatment OutcomeRecovery of FunctionRisk FactorsHemodynamics

Stichwörter der Autor:innen

Balloon-expandableMitral regurgitationMitral valveSAPIEN M3Transcatheter mitral valve replacement

Autor:innen und Institutionen

  • Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece. Electronic address: michpent@med.duth.gr.
  • School of Medicine, European University Cyprus, Nicosia, Cyprus; 3rd Department of Cardiology, Euroclinic of Athens, Athens, Greece.

Zitieren

APA

Penteris, M., & Lampropoulos, K. (2025). The SAPIEN M3 system for transcatheter mitral valve replacement: A new era begins. Cardiovascular Revascularization Medicine, 79, 120-125. https://doi.org/10.1016/j.carrev.2025.06.034

Vancouver

Penteris M, Lampropoulos K. The SAPIEN M3 system for transcatheter mitral valve replacement: A new era begins. Cardiovascular Revascularization Medicine. 2025;79:120-125. doi:10.1016/j.carrev.2025.06.034

BibTeX
@article{Penteris2025,
  author = {Penteris, Michail and Lampropoulos, Konstantinos},
  title = {The SAPIEN M3 system for transcatheter mitral valve replacement: A new era begins},
  journal = {Cardiovascular Revascularization Medicine},
  year = {2025},
  volume = {79},
  pages = {120--125},
  doi = {10.1016/j.carrev.2025.06.034}
}
Kostenlos starten →